Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H. Egawa N, et al. Among authors: hasegawa k, hasegawa m. Sci Transl Med. 2013 Jun 5;5(188):188lr2. doi: 10.1126/scitranslmed.3005697. Sci Transl Med. 2013. PMID: 23740898
Drug screening for ALS using patient-specific induced pluripotent stem cells.
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H. Egawa N, et al. Among authors: hasegawa k, hasegawa m. Sci Transl Med. 2012 Aug 1;4(145):145ra104. doi: 10.1126/scitranslmed.3004052. Sci Transl Med. 2012. PMID: 22855461
Absorption of Formaldehyde by Oleander (Nerium indicum).
Kondo T, Hasegawa K, Uchida R, Onishi M, Mizukami A, Omasa K. Kondo T, et al. Among authors: hasegawa k. Environ Sci Technol. 1995 Nov;29(11):2901-3. doi: 10.1021/es00011a030. Environ Sci Technol. 1995. PMID: 22206542 No abstract available.
Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance: a prospective longitudinal cohort study.
Hamada T, Oyama H, Nevo D, Tange S, Takaoka S, Kawaguchi Y, Ishigaki K, Noguchi K, Saito T, Sato T, Suzuki T, Takahara N, Tanaka M, Hasegawa K, Ushiku T, Nakai Y, Petrov MS, Fujishiro M; TOP-CREATE Study Group. Hamada T, et al. Among authors: hasegawa k. Gut. 2025 Jan 27:gutjnl-2024-333259. doi: 10.1136/gutjnl-2024-333259. Online ahead of print. Gut. 2025. PMID: 39870394
[Guidelines for presymptomatic genetic testing for adult-onset hereditary neuromuscular diseases in Japan].
Shibata Y, Chang H, Nakamura K, Yamada S, Matsushima M, Saigoh K, Ishiura H, Sekijima Y, Maruyama H, Ikeuchi T, Hasegawa K, Aoki M, Katsuno M, Toda T, Yabe I; Committee on Medical Genetics, Japanese Society of Neurology. Shibata Y, et al. Among authors: hasegawa k. Rinsho Shinkeigaku. 2025 Jan 24. doi: 10.5692/clinicalneurol.cn-002049. Online ahead of print. Rinsho Shinkeigaku. 2025. PMID: 39864867 Japanese.
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors.
Hayato S, Hamuro L, Shimizu T, Yonemori K, Nishio S, Yunokawa M, Yoshida T, Nishio M, Matsumoto K, Takehara K, Hasegawa K, Kozuki T, Hirashima Y, Kato H, Miura T, Nomoto M, Zhao Y, Zhu L, Yasuda S. Hayato S, et al. Among authors: hasegawa k. J Clin Pharmacol. 2025 Jan 24. doi: 10.1002/jcph.6187. Online ahead of print. J Clin Pharmacol. 2025. PMID: 39853764
Frequency of anti-IgLON5 disease in patients with a typical clinical presentation of progressive supranuclear palsy/corticobasal syndrome.
Ono Y, Takigawa H, Takekoshi A, Yoshikura N, Aiba I, Hanajima R, Kowa H, Kanazawa M, Tokuda T, Tokumaru AM, Morita M, Hasegawa K, Nakashima K, Ikeuchi T, Kimura A, Shimohata T; JALPAC Study Group. Ono Y, et al. Among authors: hasegawa k. Parkinsonism Relat Disord. 2025 Jan 15:107289. doi: 10.1016/j.parkreldis.2025.107289. Online ahead of print. Parkinsonism Relat Disord. 2025. PMID: 39843325
Identification of factors related to functional prognoses in craniopharyngiomas.
Umeda T, Otani Y, Fujii K, Ishida J, Hirano S, Suruga Y, Kemmotsu N, Imoto R, Kegoya Y, Mizuta R, Inoue Y, Hokama M, Makihara S, Hasegawa K, Inagaki K, Otsuka F, Yasuhara T, Tanaka S. Umeda T, et al. Among authors: hasegawa k. J Neurooncol. 2025 Jan 22. doi: 10.1007/s11060-024-04925-7. Online ahead of print. J Neurooncol. 2025. PMID: 39841323
An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier.
Higashi-Kuwata N, Bulut H, Hayashi H, Tsuji K, Ogata-Aoki H, Kiso M, Takamune N, Kishimoto N, Hattori SI, Ishii T, Kobayakawa T, Nakano K, Shimizu Y, Das D, Saruwatari J, Hasegawa K, Murayama K, Sukenaga Y, Takamatsu Y, Yoshimura K, Aoki M, Furusawa Y, Okamura T, Yamayoshi S, Kawaoka Y, Misumi S, Tamamura H, Mitsuya H. Higashi-Kuwata N, et al. Among authors: hasegawa k. PNAS Nexus. 2025 Jan 7;4(1):pgae578. doi: 10.1093/pnasnexus/pgae578. eCollection 2025 Jan. PNAS Nexus. 2025. PMID: 39831159 Free PMC article.
4,493 results